24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
The shift from traditional chemistry toward complex biopharmaceutical innovations, such as mAbs and RNA-based products, is fundamentally rewriting the pharmaceutical playbook. This is not only a change in what is being made, but a shift in how it is sourced and validated. From tighter scrutiny on API traceability to changes in manufacturing plant design, every stage of the supply chain is under pressure to evolve. Success now requires a holistic approach to capital planning and supplier qualification that looks far beyond the laboratory bench.
The balance of new therapies is changing. In its 2024 annual report, the European Medicines Agency (EMA) said it received 121 applications for initial evaluation of new medicines and noted a rise in activity in the PRIority MEdicines (PRIME) programme, its pathway for products with major therapeutic promise. In parallel, the WHO said demand for new and replacement standards for biological products had increased, requiring more frequent expert meetings.
This shift matters because biologic drug production is less forgiving than conventional small-molecule manufacture. Cell-derived materials, viral safety controls, cold-chain dependence and potency assays all place greater pressure on supplier qualification and site readiness. A plant that once focused on standard oral solids may now need segregated suites, tighter environmental control and stronger comparability data before scale-up decisions can move forward.
API development is also becoming more process-intensive. The International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q13, reflected by EMA guidance, covers continuous manufacturing for both chemical entities and therapeutic proteins. Manufacturers no longer judge a route only by yield. They are judging it by residence-time control, impurity behaviour, data capture, and whether the process can survive transfer from the pilot line to commercial output without reopening core validation work.
In the Eurasian context, that process discipline is becoming more visible in formal requirements. The Eurasian Economic Commission has continued to update pharmacopoeial texts, with compliance dates extending into 2026 and beyond for some applications, while official EAEU reporting in 2024 pointed to growth in applications and GMP certification activity under common Union rules. For QA and regulatory teams, that means API route changes, solvent controls, and analytical methods need to be assessed not only for technical merit but also for dossier fit and inspection readiness across markets.
Formulation is now carrying more of the therapeutic burden. Lipid nanoparticles, targeted carriers, and modified-release systems are being used to protect fragile payloads, direct tissue exposure, and manage release profiles in ways that standard formulations cannot. EMA’s 2025 draft guideline on the quality aspects of mRNA vaccines signals where the direction is heading: critical excipients, such as lipid nanoparticle components, need dedicated assays to assess their impact on bioactivity or stability.
For formulation scientists and QA managers, the implication is straightforward. Delivery systems create additional layers of control. Modified-release products already require in vitro and pharmacokinetic evidence to justify their performance, and nanoparticle-based products add additional work on particle characterisation, sterility, endotoxins, container-closure integrity, and change control. Validation packages become heavier as formulations become more specialised.
Supply chain decisions now have a greater impact on product quality than many procurement teams would like. Growth in biologics, cell and gene therapies, and complex injectables is increasing reliance on specialist excipients, sterile consumables, and tightly controlled logistics. This shift raises exposure to single-source materials and limited-capacity suppliers, particularly for lipid systems, high-purity solvents and advanced filtration components.
For the Eurasian pharma market, resilience depends on disciplined supplier qualification and realistic sourcing architecture. Dual sourcing is gaining traction where material criticality allows. CDMO services are also becoming more relevant for firms that need pilot batches, tech transfer support, or specialist fill-finish capacity without immediately committing to new capital expenditure. In practice, the strongest sourcing model is the one that ties vendor approval, quality agreements, logistics planning, and batch release expectations into a single operating plan from the outset.
Pharmtech & Ingredients connects manufacturers with suppliers of equipment, ingredients, contract services and pharmaceutical production technologies across the Eurasian pharma market. Submit a Pharmtech exhibit enquiry to meet qualified buyers, compare solutions and engage with decision-makers shaping biopharmaceutical innovation and API development.
